Program
dotinurad
Also written as “FYU-981”, “Dotinurad” and “FYU-981, (Oral single dosing)”.
Its studies are mostly in Gout · Hyperuricemia · Hepatic Insufficiency · Renal Insufficiency, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fuji Yakuhin | 110 open or running | phase 3since Dec 28, 2016 | Jan 16, 2015 | none ahead |
| Mochida Pharmaceutical | 50 open or running | phase 3since Dec 10, 2017 | Sep 20, 2017 | none ahead |
| Crystalys Therapeutics | 33 open or running | phase 3since Jul 22, 2025 | Jul 22, 2025 | Jul 2027phase 2 · NCT07535034 |
| Eisai | 20 open or running | phase 3since Aug 11, 2021 | Aug 11, 2021 | none ahead |
| Urica Therapeutics | 10 open or running | phase 2since Sep 7, 2023 | Sep 7, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Jan 16, 2015.
- Jul 29, 2015Phase 2 study in HealthyFuji Yakuhin · NCT02515864 · 48 enrolled · Japan
- Jul 15, 2016Phase 2 study in HyperuricemiaFuji Yakuhin · NCT02837198 · 24 enrolled · Japan
- Sep 12, 2016Phase 2 study in Healthy Male SubjectsFuji Yakuhin · NCT02901366 · 6 enrolled · Japan
- Dec 28, 2016Phase 3 study in Hyperuricemia With or Without GoutFuji Yakuhin · NCT03006445 · 330 enrolled · Japan
- Mar 29, 2017Phase 3 study in Hyperuricemia With or Without GoutFuji Yakuhin · NCT03100318 · 201 enrolled · Japan
- Sep 20, 2017Mochida Pharmaceutical's first study: phase 1 study in Hepatic InsufficiencyNew to Mochida PharmaceuticalMochida Pharmaceutical · NCT03306667 · 24 enrolled · Japan
- Nov 19, 20172 phase 1 studies in HealthyMochida Pharmaceutical · NCT03350386, NCT03350373
- Dec 10, 2017Phase 1 study in Hyperuricemia With or Without GoutMochida Pharmaceutical · NCT03375632 · 26 enrolled · Japan
- Dec 10, 2017Phase 3 study in Hyperuricemia With or Without GoutMochida Pharmaceutical · NCT03372200 · 203 enrolled · Japan
- Aug 11, 2021Eisai's first study: phase 3 study in GoutNew to EisaiEisai · NCT05007392 · 451 enrolled · China
- Feb 18, 2022Phase 1 study in Healthy VolunteersEisai · NCT05278676 · 26 enrolled · China
- Sep 7, 2023Urica Therapeutics's first study: phase 2 study in GoutNew to Urica TherapeuticsUrica Therapeutics · NCT06056570 · 20 enrolled · United States
- Jul 22, 2025Crystalys Therapeutics's first studies: 2 phase 3 studiesNew to Crystalys TherapeuticsCrystalys Therapeutics · NCT07089888, NCT07089875
- Apr 10, 2026Phase 2 study in GoutCrystalys Therapeutics · NCT07535034 · 90 planned · United States
Ahead
- Jul 2027Primary completion: phase 2 study in GoutCrystalys Therapeutics · NCT07535034
- Nov 29, 2027Primary completion: phase 3 study in GoutCrystalys Therapeutics · NCT07089875
- Dec 31, 2027Primary completion: phase 3 study in HyperuricemiaCrystalys Therapeutics · NCT07089888
TargetBeta
“Solute carrier family 22 member 12 inhibitor”ChEMBL 37, by rule
Other programs on SLC22A12
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruzinuradrule | Jiangsu HengRui Medicine | phase 3 | 20 |
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07535034Gout · United States | 2 | Recruiting | Crystalys Therapeutics | Jul 2027 | 90 |
| NCT07089888Hyperuricemia · United States | 3 | Recruiting | Crystalys Therapeutics | Dec 31, 2027 | 250 |
| NCT07089875Gout · United States, Poland, Spain | 3 | Recruiting | Crystalys Therapeutics | Nov 29, 2027 | 500 |
| NCT06056570Gout · United States | 2 | Completed | Urica Therapeutics | Jun 27, 2024 | 20 |
| NCT05278676Healthy Volunteers · China | 1 | Completed | Eisai | Dec 13, 2022 | 26 |
| NCT05007392Gout · China | 3 | Completed | Eisai | Jun 14, 2023 | 451 |
| NCT03375632Hyperuricemia With or Without Gout · Japan | 1 | Completed | Mochida Pharmaceutical | May 29, 2018 | 26 |
| NCT03372200Hyperuricemia With or Without Gout · Japan | 3 | Completed | Mochida Pharmaceutical | Jun 4, 2018 | 203 |
| NCT03350386Healthy · Japan | 1 | Completed | Mochida Pharmaceutical | Dec 5, 2017 | 12 |
| NCT03350373Healthy · Japan | 1 | Completed | Mochida Pharmaceutical | Nov 29, 2017 | 12 |
| NCT03306667Hepatic Insufficiency · Japan | 1 | Completed | Mochida Pharmaceutical | Jun 20, 2018 | 24 |
| NCT03100318Hyperuricemia With or Without Gout · Japan | 3 | Completed | Fuji Yakuhin | Apr 25, 2018 | 201 |
| NCT03006445Hyperuricemia With or Without Gout · Japan | 3 | Completed | Fuji Yakuhin | Aug 23, 2018 | 330 |
| NCT02901366Healthy Male Subjects · Japan | 2 | Completed | Fuji Yakuhin | Jan 2017 | 6 |
| NCT02837198Hyperuricemia · Japan | 2 | Completed | Fuji Yakuhin | Aug 2017 | 24 |
| NCT02515864Healthy · Japan | 2 | Completed | Fuji Yakuhin | Mar 2016 | 48 |
| NCT02416167Hyperuricemia · Japan | 2 | Completed | Fuji Yakuhin | May 2016 | 200 |
| NCT02348333Healthy · Japan | 1 | Completed | Fuji Yakuhin | Nov 2013 | 18 |
| NCT02348307Healthy · Japan | 1 | Completed | Fuji Yakuhin | Jun 2013 | 54 |
| NCT02344875Healthy · Japan | 1 | Completed | Fuji Yakuhin | Jun 2014 | 24 |
| NCT02344862Hyperuricemia · Japan | 2 | Completed | Fuji Yakuhin | Jul 2014 | 80 |
| NCT02347046Renal Insufficiency · Japan | 1 | Completed | Fuji Yakuhin | Mar 2015 | 18 |
How it is read
Names in the registry
- “FYU-981”, 10 entries
- “Dotinurad”, 5 entries
- “FYU-981, (Oral single dosing)”, 3 entries
- “dotinurad”, 1 entry
- “dotinurad + allopurinol”, 1 entry
Conditions, from the studies’ own filings
- Gout, 8 studies
- Hyperuricemia, 4 studies
- Hepatic Insufficiency, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.